Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Fluocinolone insert...

    Fluocinolone insert improves Diabetic Macular Edema after Vitrectomy

    Written by Vinay Singh singh Published On 2018-09-28T19:10:25+05:30  |  Updated On 28 Sept 2018 7:10 PM IST
    Fluocinolone insert improves Diabetic Macular Edema after Vitrectomy

    A new study presented at the 18th Congress of the European Society of Retina Specialists (EURETINA) showed that the long-term steroid fluocinolone acetonide intravitreal insert is effective in managing diabetic macular edema (DME) in both vitrectomized and non-vitrectomized eyes.


    Albert Augustin, MD, and presenter of the study said that fluocinolone acetonide can be used in vitrectomized eyes without loss of efficacy or a reduced duration of the treatment modality.


    The researchers retrospectively analyzed data from 63 diabetic patients (81 eyes) who had been diagnosed with DME and treated with a fluocinolone acetonide using the ILUVIEN 190 mcg intravitreal implant in the applicator, a product approved for use in Europe that delivers sustained multiyear sub-microgram levels of fluocinolone acetonide. Out of the total study participants,39 patients had previously undergone a pars plana vitrectomy (PPV).


    The average age of the patients included in the study was 67.2 ± 10 years for patients in the PPV group and 68.8 ± 10.8 years in the non-PPV group. Mean duration of DME for patients in the PPV group was 4.6 ± 2.48 years in the PPV group and 3.2 ± 3.2 years in the non-PPV group.


    The patients were assessed for efficacy outcomes, including visual acuity and central macular thickness, and safety outcomes, including intraocular pressure (IOP), at baseline and after 3 years of follow up.

    Read Also; First AI based medical device to detect diabetic retinopathy approved


    Key study findings:




    • The visual acuity, measured using ETDRS letters, improved by 5.4 letters (30 months) or 2.7 letters (36 months)

    • Subgroup analysis showed that PPV eyes improved by 1.4 letters (30 months) or 2.1 letters (36 months) letters, whereas non-PPV eyes improved by 2.9 letters (30 months) or 4.1 letters (36 months).

    • The fluocinolone acetonide implant produced an improvement in central macular thickness among all included patients of 143 μm at 30 months and 158 μm at 36 months.

    • In a subgroup analysis, changes in thickness were 125 μm at 30 months and 176 μm at 36 months in PPV eyes and 160 μm at 30 months and 137 μm at 36 months in non-PPV eyes.


    Explaining the difference in safety outcome represented by the additional use of IOP-lowering medications among patients with PPV eyes, Dr. Augustin said that vitrectomized eyes are usually eyes with a more severe alteration of the retina. In addition, those patients are also suffering from a more advanced stage of diabetes mellitus, systemic alterations.


    Dr. Augustin noted that it “was really surprising that PPV eyes respond very well to this long-acting steroid, showing that a long-term anti-inflammatory strategy is needed in those patients.” He added that anti-inflammatory therapy “should be introduced earlier in the treatment of DME.”


    According to Dr. Augustin, long-term therapy with fluocinolone acetonide even given as a very late second-line treatment has a more pronounced effect on patients’ vision and central retinal thickness with fewer interventions over 3 years.


    Follow up care can often be complicated as patients with diabetes and DME often have multiple comorbidities. So, a long-term treatment such as a fluocinolone acetonide implant “offers a big advantage for patients already needing many visits in clinics and practices.


    “The burden of treatment for these diabetic patients with DME is markedly reduced with a long-term steroid therapy,” concluded Dr. Augustin.

    diabetesdiabeticDMEedemaeffectiveEuretinaEuropean Society of Retina SpecialistsEyefluocinolone acetonideIntravitrealIOPlong termmacularmanagementpars plana vitrectomyPPVSteroidupdatesvitrectomized
    Source : With inputs from European Society of Retina Specialists

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok